Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Abstract Background Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB09004 evaluated masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate dementia...

Full description

Bibliographic Details
Main Authors: Bruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, Triantafyllos Doskas, Luiza Spiru, Svitlana Moroz, Olena Venger, Patrick Vermersch, Alain Moussy, Colin D. Mansfield, Olivier Hermine, Magda Tsolaki, for the AB09004 Study Group Investigators
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Mast cells
Microglia
Tyrosine kinase inhibitor
Online Access:https://doi.org/10.1186/s13195-023-01169-x

Internet

https://doi.org/10.1186/s13195-023-01169-x

Similar Items